Delivery Order SPE2DB25D3012-SPE2DB25FWYEE

Award Date 6/25/25
Potential Completion Date 7/17/25
Potential Value $11K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,871.50 firm fixed-price contract is for the delivery of TAGRISSO 40 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of January 17, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical,...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 30-count tablets of the prescription drug Tagrisso at a firm fixed price of $10,641.07. The contract has an ultimate completion date of July 17, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued at $999,999,999.00,...
This is a $21,325.14 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of TAGRISSO 80 MG TABLET 30S, a prescription medication, with a period of performance through July 3, 2025. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive global...
This is a $10,662.57 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of TAGRISSO 80 MG TABLET 30S. The contract has an ultimate completion date of July 15, 2025 and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a comprehensive global pharmaceutical...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The contract, valued at $10,903.03, is for the supply of TAGRISSO 80 MG TABLET 30S, a prescription medication. This order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 between AmerisourceBergen and the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of the cancer drug TAGRISSO 40 MG TABLET 30S. The contract has a ceiling value of $21,016.64 and a period of performance through October 16, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 that AmerisourceBergen holds with DLA Troop Support Medical for providing a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation for the supply of TAGRISSO 40 MG TABLET 30S, a pharmaceutical product. The contract has a ceiling value of $21,016.64 and is a firm fixed-price delivery order. The period of performance ends on September 4, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued at up to $999,999,999 through...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the provision of TAGRISSO 80 MG TABLET 30S, a prescription medication. The contract has a firm fixed price of $10,662.57 and is set to expire on March 26, 2025. This contract does not have a set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp holds a significant Indefinite...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of TAGRISSO 80 MG TABLET 30S, a pharmaceutical product, with a ceiling value of $21,325.14 and a period of performance through June 12, 2025. The contract is a firm fixed-price delivery order, without any set-aside designation, indicating open competition. AmerisourceBergen Drug Corp...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $10,662.57 contract is for the delivery of TAGRISSO 80 MG TABLET 30S, a prescription medication, with a performance period ending on May 23, 2025. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
  • SPE2DB25D3012
    Indefinite Delivery Contract
  • SPE2DB25D3012-SPE2DB25FWYEE
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the drug TAGRISSO 80 MG TABLET 30S. The contract has a firm fixed price of $10,662.57 and a period of performance through July 17, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00 held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive global pharmaceutical support vehicle with a performance period through December 2026. The contract is not designated as a set-aside.

Generated 9/24/25, 10:56 AM